SG11201401949YA - Nadph oxidase 4 inhibitors and use thereof - Google Patents
Nadph oxidase 4 inhibitors and use thereofInfo
- Publication number
- SG11201401949YA SG11201401949YA SG11201401949YA SG11201401949YA SG11201401949YA SG 11201401949Y A SG11201401949Y A SG 11201401949YA SG 11201401949Y A SG11201401949Y A SG 11201401949YA SG 11201401949Y A SG11201401949Y A SG 11201401949YA SG 11201401949Y A SG11201401949Y A SG 11201401949YA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- nadph oxidase
- nadph
- oxidase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11188782.4A EP2591782A1 (en) | 2011-11-11 | 2011-11-11 | Nadph oxidase 4 inhibitors and use thereof |
PCT/IB2012/056286 WO2013068972A1 (en) | 2011-11-11 | 2012-11-09 | Nadph oxidase 4 inhibitors and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201401949YA true SG11201401949YA (en) | 2014-05-29 |
Family
ID=47326276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201401949YA SG11201401949YA (en) | 2011-11-11 | 2012-11-09 | Nadph oxidase 4 inhibitors and use thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US20140323500A1 (en) |
EP (2) | EP2591782A1 (en) |
JP (1) | JP6228921B2 (en) |
KR (1) | KR101943141B1 (en) |
CN (1) | CN103945844A (en) |
AU (1) | AU2012335148A1 (en) |
BR (1) | BR112014011400A2 (en) |
CA (1) | CA2855004A1 (en) |
ES (1) | ES2638596T3 (en) |
HK (1) | HK1200029A1 (en) |
IL (1) | IL232515A0 (en) |
MX (1) | MX2014005440A (en) |
RU (1) | RU2014123672A (en) |
SG (1) | SG11201401949YA (en) |
WO (1) | WO2013068972A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2591782A1 (en) | 2011-11-11 | 2013-05-15 | Johann Wolfgang Goethe-Universität | Nadph oxidase 4 inhibitors and use thereof |
EP2857399A1 (en) * | 2013-10-03 | 2015-04-08 | GenKyoTex SA | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction |
EP3034500A1 (en) * | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
EP3098220A1 (en) | 2015-05-28 | 2016-11-30 | GenKyoTex SA | Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof |
CA2989098A1 (en) | 2015-06-22 | 2016-12-29 | Actelion Pharmaceuticals Ltd | Nadph oxidase 4 inhibitors |
WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
EP3479843A1 (en) | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
CN109045276B (en) * | 2018-09-26 | 2021-04-13 | 武汉大学 | Application of bleomycin in preparation of medicine for inhibiting tooth eruption |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2021172982A1 (en) | 2020-02-26 | 2021-09-02 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1291017A3 (en) * | 2001-09-10 | 2003-07-02 | Warner-Lambert Company | Use of statins to inhibit formation of osteoclasts |
EP2002835A1 (en) * | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
US20090163452A1 (en) * | 2007-12-20 | 2009-06-25 | Schwartz Janice B | Compositions and methods for lowering serum cholesterol |
EP2166010A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2165707A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2521453B1 (en) * | 2010-01-08 | 2016-05-11 | Beth Israel Deaconess Medical Center | Combinations of vitamin d and a statin for the treatment of migraine headaches |
EP2591782A1 (en) | 2011-11-11 | 2013-05-15 | Johann Wolfgang Goethe-Universität | Nadph oxidase 4 inhibitors and use thereof |
-
2011
- 2011-11-11 EP EP11188782.4A patent/EP2591782A1/en not_active Withdrawn
-
2012
- 2012-11-09 RU RU2014123672/15A patent/RU2014123672A/en not_active Application Discontinuation
- 2012-11-09 ES ES12798879.8T patent/ES2638596T3/en active Active
- 2012-11-09 CN CN201280055349.4A patent/CN103945844A/en active Pending
- 2012-11-09 AU AU2012335148A patent/AU2012335148A1/en not_active Abandoned
- 2012-11-09 KR KR1020147015435A patent/KR101943141B1/en active IP Right Grant
- 2012-11-09 MX MX2014005440A patent/MX2014005440A/en unknown
- 2012-11-09 SG SG11201401949YA patent/SG11201401949YA/en unknown
- 2012-11-09 BR BR112014011400A patent/BR112014011400A2/en not_active IP Right Cessation
- 2012-11-09 CA CA2855004A patent/CA2855004A1/en not_active Abandoned
- 2012-11-09 JP JP2014540618A patent/JP6228921B2/en active Active
- 2012-11-09 US US14/357,605 patent/US20140323500A1/en not_active Abandoned
- 2012-11-09 EP EP12798879.8A patent/EP2776027B1/en active Active
- 2012-11-09 WO PCT/IB2012/056286 patent/WO2013068972A1/en active Application Filing
-
2014
- 2014-05-08 IL IL232515A patent/IL232515A0/en unknown
- 2014-12-24 HK HK14112914.2A patent/HK1200029A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2014533263A (en) | 2014-12-11 |
EP2776027A1 (en) | 2014-09-17 |
ES2638596T3 (en) | 2017-10-23 |
JP6228921B2 (en) | 2017-11-08 |
MX2014005440A (en) | 2015-03-09 |
US20140323500A1 (en) | 2014-10-30 |
CN103945844A (en) | 2014-07-23 |
CA2855004A1 (en) | 2013-05-16 |
EP2776027B1 (en) | 2017-06-07 |
IL232515A0 (en) | 2014-06-30 |
BR112014011400A2 (en) | 2017-05-02 |
EP2591782A1 (en) | 2013-05-15 |
HK1200029A1 (en) | 2015-07-31 |
AU2012335148A1 (en) | 2014-05-29 |
WO2013068972A1 (en) | 2013-05-16 |
RU2014123672A (en) | 2015-12-20 |
KR101943141B1 (en) | 2019-01-28 |
KR20140089591A (en) | 2014-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1200029A1 (en) | Nadph oxidase 4 inhibitors and use thereof nadph 4 | |
ZA201400141B (en) | Keto-isovalerate decarboxylase enzymes and methods of use thereof | |
EP2678018A4 (en) | Combination of kanase inhibitors and uses thereof | |
HK1198827A1 (en) | Dyrk1 inhibitors and uses thereof dyrk1 | |
IL222361A0 (en) | Lysine specific demethylase-1 inhibitors and their use | |
EP2619184A4 (en) | Deubiquitinase inhibitors and methods for use of the same | |
PT2739695T (en) | Adhesives and use thereof | |
ZA201307331B (en) | Herbicidal composition comprising plazasulfuron and an inhibitor of protoporphyrinogen oxidase | |
EP2545161A4 (en) | Enterobacter sp. 638 and methods of use thereof | |
IL232977A0 (en) | Intranasal dexmedetomidine compositins and methods of use thereof | |
EP2726467A4 (en) | Macrocyclic insulin-degrading enzyme (ide) inhibitors and uses thereof | |
EP2663864B8 (en) | Immunodiversity assessment method and its use | |
AP2014007679A0 (en) | Use of inhibitors of the activity or function of P13K | |
HK1191034A1 (en) | N-carboxyalkyl-auristatins and use thereof n- | |
IL229631A0 (en) | Lysyl oxidase-like2 assay and methods of use thereof | |
ZA201301795B (en) | Inhibitors of notum pectinacetylesterase and methods of their use | |
HK1198122A1 (en) | Eosinophil peroxidase compositions and methods of their use | |
EP2536709A4 (en) | Prolylhydroxylase inhibitors and methods of use | |
EP2556055A4 (en) | Ship inhibitors and uses thereof | |
EP2688901A4 (en) | INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 | |
GB2478317B (en) | Herbicidal composition and method of use thereof | |
EP2488179A4 (en) | Nrf2 inhibitors and use thereof | |
HUE037704T2 (en) | Herbicidal composition and method of using the same | |
HUP1200402A2 (en) | Lysyl oxidase inhibitors and their use | |
GB201004309D0 (en) | New enzyme inhibitors |